The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase II study assessing efficacy and tolerance of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in first-line metastatic colorectal cancer (MCRC): The Omega Trial (NTC 00467142).
Jacques Robert
No relevant relationships to disclose
Yves Becouarn
No relevant relationships to disclose
Laurent Cany
No relevant relationships to disclose
Marina Pulido
No relevant relationships to disclose
Jérôme Dauba
No relevant relationships to disclose
Richard Beyssac
No relevant relationships to disclose
Dominique Bechade
No relevant relationships to disclose
Caroline Lalet
No relevant relationships to disclose
Simone Mathoulin-Pelissier
No relevant relationships to disclose
Rene Brunet
No relevant relationships to disclose
Marianne Fonck
No relevant relationships to disclose